LSEQ yields 1.84% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, LSEQ + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LSEQ + PFE for your $10,000?
LSEQ is the first known hedge fund to ETF conversion in the industry. The fund aims to optimize returns while managing risk amid evolving market conditions by balancing long and short positions in US large and mid-cap stocks. The fund utilizes a multifactor model for long positions and a dedicated short model to identify potential underperformers. The approach is a proprietary macroeconomic regime model, which classifies market environments into value, neutral, or momentum regimes. This model determines gross and net exposure levels, value, quality, profitability, and momentum. Industry group selection is based on perceived alpha opportunities, focusing on sectors exhibiting the highest return dispersion. To manage risk, the fund maintains long and short exposures to counteract downside tail risk, gauged by the Sortino ratio. Investments may include T-bills, derivatives, limited foreign exposure, and reverse repurchase agreements. LSEQ started with $3.64 million in net assets.
Full LSEQ Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.